迷走神経刺激の市場規模、シェア、成長分析：製品タイプ別、用途別、生体材料別、エンドユーザー別、地域別 - 産業予測 2025～2032年

迷走神経刺激市場規模は2023年に5億799万米ドルと評価され、2024年の5億5,015万米ドルから2032年には10億4,115万米ドルに成長し、予測期間（2025～2032年）のCAGRは8.3％で成長する見通しです。

迷走神経刺激（VNS）市場は、高齢者人口の増加、技術の進歩、てんかんや片頭痛などの慢性疾患の補助療法としてのVNS需要の高まりなど、いくつかの重要な要因によって力強い成長を遂げています。てんかん発作の50%減少によって証明されたこの治療器の有効性と慢性うつ病治療への応用は、今後6年間の市場力学を強化する上で極めて重要です。パンデミックに関連した病院へのアクセス制限により2020年には頓挫するものの、遠隔診察の台頭がこうした影響を緩和するのに役立っています。さらに、神経疾患の有病率の高さと低侵襲的処置の動向は、VNS市場の可能性をさらに際立たせ、世界的に重要なアンメット・メディカル・ニーズへの対応におけるVNSの重要な役割を浮き彫りにしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

迷走神経刺激市場規模：製品タイプ別

• 市場概要
• 埋め込み型VNSデバイス
• 外部VNSデバイス

迷走神経刺激市場規模：用途別

• 市場概要
• てんかん
• うつ
• 片頭痛
• その他

迷走神経刺激市場規模：生体材料別

• 市場概要
• メタリック
• セラミックス
• その他

迷走神経刺激市場規模：エンドユーザー別

• 市場概要
• 病院
• 専門クリニック
• 外来手術センター

迷走神経刺激市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• LivaNova PLC（UK）
• ElectroCore, Inc.（USA）
• Cyberonics, Inc.（USA）
• Boston Scientific Corporation（USA）
• Medtronic PLC（Ireland）
• NeuroPace, Inc.（USA）
• Aleva Neurotherapeutics SA（Switzerland）
• BioControl Medical（Israel）
• Inspire Medical Systems, Inc.（USA）
• Nervana, LLC（USA）
• ReShape Lifesciences Inc.（USA）
• SetPoint Medical（USA）
• Soterix Medical Inc.（USA）
• tVNS Technologies GmbH（Germany）
• Parasym Ltd.（UK）
• Cerbomed GmbH（Germany）
• MicroTransponder Inc.（USA）
• NeuroSigma, Inc.（USA）
• BioElectronics Corporation（USA）
• Nexstim Plc（Finland）

結論と提言

Vagus Nerve Stimulation Market size was valued at USD 507.99 million in 2023 and is poised to grow from USD 550.15 million in 2024 to USD 1041.15 million by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The vagus nerve stimulation (VNS) market is experiencing robust growth driven by several key factors, including the increasing elderly population, advancements in technology, and a rising demand for VNS as an adjunct therapy for chronic conditions like epilepsy and migraines. The devices' effectiveness, evidenced by a 50% reduction in epileptic seizures, combined with their application in chronic depression treatment, are pivotal in enhancing market dynamics over the next six years. Despite setbacks in 2020 due to pandemic-related hospital access restrictions, the rise of teleconsultations has helped mitigate these impacts. Additionally, the high prevalence of neurological disorders and the trend toward minimally invasive procedures further underscore the VNS market's potential, highlighting its significant role in addressing critical unmet medical needs globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vagus Nerve Stimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vagus Nerve Stimulation Market Segments Analysis

Global Vagus Nerve Stimulation Market is segmented by Product Type, Application, Biomaterial, End User and region. Based on Product Type, the market is segmented into Implantable VNS Devices and External VNS Devices. Based on Application, the market is segmented into Epilepsy, Depression, Migraine and Others. Based on Biomaterial, the market is segmented into Metallic, Ceramics and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vagus Nerve Stimulation Market

The increasing number of elderly individuals, who are more vulnerable to a range of neurological disorders, is significantly fueling the demand for advanced treatment solutions such as Vagus Nerve Stimulation (VNS). This innovative therapy offers hope for improving the quality of life for patients suffering from these conditions. As the elderly population continues to expand, the necessity for effective treatments that address their specific health challenges becomes crucial, thereby propelling the growth of the VNS market. This trend highlights the urgent need for novel medical interventions tailored to enhance the well-being of older adults facing neurological issues.

Restraints in the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation (VNS) market faces significant constraints due to the high costs associated with implantation procedures and the ongoing maintenance of the devices. These financial burdens can create affordability issues for patients, particularly those who may not have adequate insurance coverage or financial resources. Furthermore, healthcare systems may also struggle to allocate funds for such expensive treatments, which could limit accessibility for a broader patient population. As a result, the high expenses associated with VNS could hinder its adoption and utilization, impacting market growth and patient outcomes in the long term.

Market Trends of the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation (VNS) market is experiencing a notable trend towards non-invasive solutions, as advancements in technology yield devices that are more accessible and patient-friendly. This shift addresses longstanding concerns surrounding invasive procedures, making VNS therapy a viable option for a broader range of patients, including those who may be hesitant to undergo surgical interventions. The increasing awareness of the benefits of VNS, coupled with growing incidences of conditions such as epilepsy and depression, is driving demand. This trend is expected to foster innovation and competition, ultimately enhancing treatment options and improving patient outcomes in the thriving VNS market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Vagus Nerve Stimulation Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Implantable VNS Devices
• External VNS Devices

Global Vagus Nerve Stimulation Market Size by Application & CAGR (2025-2032)

• Market Overview
• Epilepsy
• Depression
• Migraine
• Others

Global Vagus Nerve Stimulation Market Size by Biomaterial & CAGR (2025-2032)

• Market Overview
• Metallic
• Ceramics
• Others

Global Vagus Nerve Stimulation Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Global Vagus Nerve Stimulation Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Biomaterial, End User)
  • US
  • Canada
• Europe (Product Type, Application, Biomaterial, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Biomaterial, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Biomaterial, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Biomaterial, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ElectroCore, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyberonics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroPace, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aleva Neurotherapeutics SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioControl Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inspire Medical Systems, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nervana, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReShape Lifesciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetPoint Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Soterix Medical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• tVNS Technologies GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parasym Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbomed GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroTransponder Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroSigma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioElectronics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nexstim Plc (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations